BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 10, 2000
View Archived Issues
ICN acquires three products from Wyeth-Pharma
Read More
Role for COX-2 in ischemic damage produced by NO
Read More
CRL-1072 enhances antibiotic activity against MAI
Read More
Merck describes novel penems with activity against resistant staphylococci
Read More
New series of NK2 receptor antagonists developed at Pfizer
Read More
Agents for improving insulin resistance designed by AHP scientists
Read More
Korean lab focuses on fumagillol derivatives as angiogenesis inhibitors
Read More
NC-1175 possesses ATPase-targeted antifungal activity
Read More
Centaur continues research into potential new treatments for IBD
Read More
Olanzapine and fluoxetine in combination useful for refractory depression
Read More
Rat adjuvant arthritis ameliorated by thalidomide analogue
Read More
The antiplatelet agent triflusal now shown to inhibit NF-kappaB activation
Read More
Sedative/hypnotic neuroactive steroids from CoCensys successfully pass preclinical screening
Read More
Abbott's new ketolide ABT-773 will be codeveloped by Taisho
Read More
Sumitomo to develop BDNF for new indication: diabetes
Read More
Health Canada approves first pill to treat influenza
Read More
Depot avorelin produces effective, sustained and safe medical castration in prostate cancer
Read More
FDA approves liquid formulation of Celexa for treatment of depression
Read More
Isis and Elan to develop antisense drug for HCV
Read More
Another major market launch announced for infliximab
Read More
BLA submitted for PEG-Intron HCV therapy
Read More
PR39 induces therapeutic angiogenesis in preclinical models
Read More
Inspire's dry eye product enters phase II testing
Read More
BioCryst updates influenza neuraminidase inhibitor program with R.W. Johnson
Read More
Qiagen acquires Rapigene
Read More
Adult patients with chronic liver disease respond poorly to HBV vaccines
Read More
Licensing opportunity from NIH: live attenuated RSV and PIV for use as human vaccines
Read More